Home/Investors/Public market investors

Public market investors

Biotech Investor · 11 portfolio companies

Portfolio

11

Combined Value

$46.1B

Focus Areas

19

Top Stage

Phase 2

Investment Focus

Oncology Immunology Autoimmune Hematology/Oncology Cardiovascular Orthopedic Neuroscience Inflammation Inflammatory Diseases Critical Care Neurodegenerative Diseases Amyotrophic Lateral Sclerosis Rare Diseases Ophthalmology Neurology

Portfolio Companies

Company	Stage	Valuation	Focus
REVOLUTION Medicines	Phase 2	$35.1B	Oncology
Kymera Therapeutics	Phase 1b	$8.3B	Immunology, Oncology
Mesoblast	Approved	$2.0B	Hematology/Oncology, Cardiovascular
Contineum Therapeutics	Phase 2	$460.0M	Neuroscience, Immunology
InflaRx	Phase 3	$285.0M	Inflammatory Diseases, Critical Care
NeuroSense Therapeutics	Phase IIb	$31.4M	Neurodegenerative Diseases, Amyotrophic Lateral Sclerosis
Akari Therapeutics	Phase 3	$17.3M	Rare Diseases, Inflammation
NextCure	Phase 2	$6.9M	Oncology, Immunology
Unity Biotechnology	Phase 2	$3.4M	Ophthalmology, Neurology
Magenta Therapeutics	Phase 2	—	Oncology, Hematology
Innolake Biopharm	phase-3	—	Oncology, Immunology

Frequent Co-Investors

Legend Capital1 shared The Column Group1 shared Boyu Capital1 shared Vertex Ventures HC1 shared Third Rock Ventures1 shared Sanofi1 shared NovaQuest Capital Management1 shared Pivotal Bioventure Partners1 shared